JP2015520233A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520233A5
JP2015520233A5 JP2015518483A JP2015518483A JP2015520233A5 JP 2015520233 A5 JP2015520233 A5 JP 2015520233A5 JP 2015518483 A JP2015518483 A JP 2015518483A JP 2015518483 A JP2015518483 A JP 2015518483A JP 2015520233 A5 JP2015520233 A5 JP 2015520233A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
androgen receptor
related medical
compound
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015518483A
Other languages
English (en)
Japanese (ja)
Other versions
JP6392752B2 (ja
JP2015520233A (ja
Filing date
Publication date
Priority claimed from US13/525,941 external-priority patent/US8710272B2/en
Application filed filed Critical
Priority claimed from PCT/US2013/046138 external-priority patent/WO2013192091A1/en
Publication of JP2015520233A publication Critical patent/JP2015520233A/ja
Publication of JP2015520233A5 publication Critical patent/JP2015520233A5/ja
Application granted granted Critical
Publication of JP6392752B2 publication Critical patent/JP6392752B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015518483A 2012-06-18 2013-06-17 (1e,6e)−1,7−ビス−(3,4−ジメトキシフェニル)−4,4−ジ置換−ヘプタ−1,6−ジエン−3,5−ジオン構造足場を伴う化合物、その生物活性、およびその使用 Active JP6392752B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/525,941 US8710272B2 (en) 2007-01-08 2012-06-18 Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US13/525,941 2012-06-18
PCT/US2013/046138 WO2013192091A1 (en) 2012-06-18 2013-06-17 Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018090272A Division JP2018135386A (ja) 2012-06-18 2018-05-09 (1e,6e)−1,7−ビス−(3,4−ジメトキシフェニル)−4,4−ジ置換−ヘプタ−1,6−ジエン−3,5−ジオン構造足場を伴う化合物、その生物活性、およびその使用 関連出願の相互参照

Publications (3)

Publication Number Publication Date
JP2015520233A JP2015520233A (ja) 2015-07-16
JP2015520233A5 true JP2015520233A5 (enExample) 2016-09-15
JP6392752B2 JP6392752B2 (ja) 2018-09-19

Family

ID=49769258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015518483A Active JP6392752B2 (ja) 2012-06-18 2013-06-17 (1e,6e)−1,7−ビス−(3,4−ジメトキシフェニル)−4,4−ジ置換−ヘプタ−1,6−ジエン−3,5−ジオン構造足場を伴う化合物、その生物活性、およびその使用
JP2018090272A Abandoned JP2018135386A (ja) 2012-06-18 2018-05-09 (1e,6e)−1,7−ビス−(3,4−ジメトキシフェニル)−4,4−ジ置換−ヘプタ−1,6−ジエン−3,5−ジオン構造足場を伴う化合物、その生物活性、およびその使用 関連出願の相互参照

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018090272A Abandoned JP2018135386A (ja) 2012-06-18 2018-05-09 (1e,6e)−1,7−ビス−(3,4−ジメトキシフェニル)−4,4−ジ置換−ヘプタ−1,6−ジエン−3,5−ジオン構造足場を伴う化合物、その生物活性、およびその使用 関連出願の相互参照

Country Status (14)

Country Link
EP (3) EP3549581A3 (enExample)
JP (2) JP6392752B2 (enExample)
KR (1) KR102171469B1 (enExample)
CN (3) CN106220507A (enExample)
AU (1) AU2013277423B2 (enExample)
CA (1) CA2876957C (enExample)
DK (1) DK3150203T3 (enExample)
ES (1) ES2775173T3 (enExample)
HK (1) HK1211211A1 (enExample)
IN (1) IN2015MN00131A (enExample)
MX (1) MX2014015936A (enExample)
NZ (1) NZ703167A (enExample)
SG (1) SG11201408387YA (enExample)
WO (1) WO2013192091A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102693361B1 (ko) * 2017-05-26 2024-08-09 브루인 바이오사이언시스, 인크. 화학색전제
CN107226783B (zh) * 2017-06-20 2019-07-23 武汉工程大学 一种溶酶体靶向荧光探针及其制备方法
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
GB2572259B (en) * 2018-03-23 2022-03-30 Merry Life Biomedical Company Ltd Uses of curcumin derivative
JP2020117489A (ja) * 2019-01-04 2020-08-06 アリアンツ ファーマサイエンス リミテッド 脳癌の治療方法
JP2020125285A (ja) * 2019-01-04 2020-08-20 アリアンツ ファーマサイエンス リミテッド 神経変性性障害の治療方法
CN110183320B (zh) * 2019-04-15 2021-06-11 四川大学 一类多烯二酮类抗肿瘤化合物
EP4516771A4 (en) * 2022-04-29 2025-08-20 Nanjing Minova Pharmaceutical Co Ltd COMPOUND HAVING ANTI-ANDROGEN RECEPTOR ACTIVITY AND ITS USE
CN116120182A (zh) * 2023-02-16 2023-05-16 常州大学 姜黄素衍生物及其合成方法和在抗雄激素受体中的应用
CN116283676B (zh) * 2023-03-24 2025-03-28 常州大学 一种姜黄素衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US812408A (en) 1905-08-19 1906-02-13 Roy Ernest Dickerson Educational device for teaching spherics.
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US7355081B2 (en) * 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
WO2008085984A1 (en) * 2007-01-08 2008-07-17 Androscience Corporation Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
KR20100051808A (ko) * 2007-07-31 2010-05-18 앤드로사이언스 코포레이션 안드로겐 수용체 분해 강화제를 포함한 조성물 및 탈모와 피부질환의 예방 또는 치료 방법
US20090282496A1 (en) * 2008-04-04 2009-11-12 University Of Rochester Medical Center Androgen Receptor Related Methods for Treating Bladder Cancer

Similar Documents

Publication Publication Date Title
JP2015520233A5 (enExample)
KR101739800B1 (ko) 안드로겐 수용체 조절제의 에스터 유도체 및 그의 이용 방법
JP2011522822A5 (enExample)
JP2015506376A5 (enExample)
RU2015129546A (ru) Нейроактивные 19-алкокси-17-замещенные стероиды, их пролекарства и способы лечения с их применением
WO2017040993A4 (en) Small molecule inhibitors of dyrk1a and uses thereof
CN105980372B (zh) 官能化的苯并吡喃化合物及其用途
CN114026072A (zh) 治疗特发性肺纤维化的方法
JP2015524450A5 (enExample)
JP2015511609A5 (enExample)
JP2012517450A5 (enExample)
JP2014516033A5 (enExample)
JP2011046708A5 (enExample)
KR20190018486A (ko) 암의 예방 및/또는 치료를 위한 화합물, 조성물 및 방법
RU2016116789A (ru) Комбинация энзалутамида и афурезертиба для лечения рака
JP5959083B2 (ja) (1R−trans)−N−[[2−(2,3−ジヒドロ−4−ベンゾフラニル)シクロプロピル]メチル]プロパンアミドの代謝物
JP2013513625A (ja) ネホパム化合物を使用して、瘢痕およびβ−カテニン媒介障害を治療する方法
RU2016130148A (ru) Производные имидазопиразинона
JP2018523657A5 (enExample)
JP5841903B2 (ja) 肝障害の治療または肝機能の向上のための薬剤
PH12012501349A1 (en) Dp2 antagonist and uses thereof
JP2009502775A5 (enExample)
JP6433686B2 (ja) 癌治療用組成物の調製のためのイカリチンの使用
Wong et al. Oral melanosis after tyrosine kinase inhibition with imatinib for chronic myelogenous leukemia: report of a case and review of the literature
KR20230068277A (ko) 노화세포 제거용 화합물 및 이의 용도